Business
Delcath Systems, Inc. Announces Positive Results from Independent Study on Liver-Directed Therapy for Uveal Melanoma Patients
NEW YORK--(BUSINESS WIRE)-- Delcath Systems, Inc. (Nasdaq: DCTH) (the “Company” or “Delcath”), an interventional oncology company focused on the treatment of
About this update from Delcath Systems, Inc.
[{"type":"text","content":" NEW YORK--(BUSINESS WIRE)--\nDelcath Systems, Inc. (Nasdaq: DCTH) (the “Company” or “Delcath”), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today announced the publication of a clinical study in the journal Therapeutic Advances in Medical Oncology. The publication, entitled “Melanoma-specific survival of patients with uveal melanoma and liver metastases diagnosed between 2005 and 2021”, was based on an independent retrospective clinical study conducted by investigators from the University of Tübingen, Germany. The study demonstrates that first-line liver-directed therapies, including Delcath’s CHEMOSAT® Hepatic Delivery System, significantly improve melanoma-specific survival (MSS) in patients with liver metastases from uveal melanoma, compared to first-line systemic therapies.\n\n\nKey Findings from the Study:\n\n\n\nPositive Trends in Survival with First-Line Liver-Directed Therapies: The study analyzed 167 patients diagnosed with metastatic uveal melanoma between 2005 and 2021. Among those receiving first-line liver-directed therapy (N=89), the median MSS was 28 months, compared to 10 months for patients who received first-line systemic therapy (N=45).\n\n\n\n\nComparison of Outcomes Over Time with First-Line Liver-Directed Therapies: The study found that patients diagnosed with liver metastases between 2016 and 2021 (N=56) and treated with first-line liver-directed therapy, including CHEMOSAT, had a median MSS of 30 months. In comparison, patients diagnosed between 2005 and 2015 (N=33) who received first-line liver-directed therapy had a median MSS of 20 months.\n\nDuring the 2005-2015 period, 33 patients received liver-directed therapy, with 8 of those receiving CHEMOSAT. In the 2016-2021 period, 56 patients received liver-directed therapy, with 30 of those receiving CHEMOSAT.\n\n\n\nDr. Vojislav Vukovic, Chief Medical Officer of Delcath Systems, commented, “We are encouraged by the findings from this independent study, which reinforce the critical role of liver-directed therapies in the first-line setting, including our CHEMOSAT system, in treating patients with liver metastases from uveal melanoma.”\n\n\nThe publication is available here.\n\n\nAbout Delcath Systems, Inc., HEPZATO KIT and CHEMOSAT\n\n\nDelcath Systems, Inc. is an interventional oncology compa...